Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX0159-07 in Chronic Inducible Urticaria
2024-516988-87-00Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chronic inducible urticaria (CIndU) comparing Barzolvolimab with Placebo (2 arms). Primary endpoints: Proportion of ColdU patients with negative provocation test at Week 12 and Proportion of SD patients with negative provocation test at Week 12. Started Nov 2022; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on 2024-516988-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516988-87-00.